Chicago Equity Partners LLC purchased a new stake in Emergent Biosolutions, Inc. (NYSE:EBS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 46,365 shares of the biopharmaceutical company’s stock, valued at approximately $1,875,000. Chicago Equity Partners LLC owned approximately 0.11% of Emergent Biosolutions as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in EBS. OppenheimerFunds Inc. boosted its holdings in Emergent Biosolutions by 23.0% in the first quarter. OppenheimerFunds Inc. now owns 12,558 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 2,351 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Emergent Biosolutions by 0.4% in the first quarter. Teachers Advisors LLC now owns 371,322 shares of the biopharmaceutical company’s stock valued at $10,783,000 after acquiring an additional 1,618 shares in the last quarter. Legal & General Group Plc boosted its holdings in Emergent Biosolutions by 9.3% in the first quarter. Legal & General Group Plc now owns 61,140 shares of the biopharmaceutical company’s stock valued at $1,775,000 after acquiring an additional 5,213 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after acquiring an additional 238,194 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Emergent Biosolutions by 9.0% in the first quarter. Geode Capital Management LLC now owns 314,198 shares of the biopharmaceutical company’s stock valued at $9,124,000 after acquiring an additional 25,953 shares in the last quarter. Institutional investors and hedge funds own 85.97% of the company’s stock.
WARNING: “Chicago Equity Partners LLC Purchases Shares of 46,365 Emergent Biosolutions, Inc. (EBS)” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/13/chicago-equity-partners-llc-purchases-shares-of-46365-emergent-biosolutions-inc-ebs.html.
Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at $40.86 on Monday. Emergent Biosolutions, Inc. has a fifty-two week low of $25.96 and a fifty-two week high of $44.86. The company has a market cap of $1,691.42, a price-to-earnings ratio of 21.62, a PEG ratio of 1.13 and a beta of 1.22. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The firm had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the business posted $0.56 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis. sell-side analysts forecast that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current year.
A number of analysts have recently commented on EBS shares. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Emergent Biosolutions currently has an average rating of “Buy” and an average price target of $45.00.
In related news, Director Jerome M. Hauer sold 10,776 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $35.83, for a total value of $386,104.08. Following the transaction, the director now owns 29,421 shares in the company, valued at approximately $1,054,154.43. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George A. Joulwan sold 14,251 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total transaction of $587,711.24. Following the completion of the transaction, the director now owns 34,323 shares in the company, valued at approximately $1,415,480.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 225,986 shares of company stock worth $8,929,278. Company insiders own 16.50% of the company’s stock.
Emergent Biosolutions Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.